Solid Biosciences (SLDB) Return on Capital Employed (2018 - 2026)
Quarterly results put Return on Capital Employed at 66.05% for Q1 2026, down 588.0% from a year ago — trailing twelve months through Mar 2026 was 66.05% (down 588.0% YoY), and the annual figure for FY2025 was 101.17%, down 1265.0%.
Solid Biosciences has reported Return on Capital Employed over the past 9 years, most recently at 66.05% for Q1 2026.
- Return on Capital Employed reached 66.05% in Q1 2026 per SLDB's latest filing, up from 81.55% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 40.73% in Q1 2022 and bottomed at 81.55% in Q4 2025.
- Median Return on Capital Employed over the past 5 years was 56.46% (2024), compared with a mean of 57.93%.
- The largest annual shift saw Return on Capital Employed tumbled -1998bps in 2022 before it soared 1249bps in 2024.
- Over 5 years, Return on Capital Employed stood at 53.26% in 2022, then fell by -22bps to 65.03% in 2023, then fell by -17bps to 76.32% in 2024, then dropped by -7bps to 81.55% in 2025, then rose by 19bps to 66.05% in 2026.
- Business Quant data shows Return on Capital Employed for SLDB at 66.05% in Q1 2026, 81.55% in Q4 2025, and 66.61% in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 21.10% |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 10.19% |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 20.34% |
| 10 | Solid Biosciences | 713.77 Mn | 333.09 Mn | - | -66.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -66.05% |
| Dec 31, 2025 | -81.55% |
| Sep 30, 2025 | -66.61% |
| Jun 30, 2025 | -52.94% |
| Mar 31, 2025 | -60.17% |
| Dec 31, 2024 | -76.32% |
| Sep 30, 2024 | -56.46% |
| Jun 30, 2024 | -44.43% |
| Mar 31, 2024 | -51.48% |
| Dec 31, 2023 | -65.03% |
| Sep 30, 2023 | -65.15% |
| Jun 30, 2023 | -56.92% |
| Mar 31, 2023 | -50.35% |
| Dec 31, 2022 | -53.26% |
| Sep 30, 2022 | -50.42% |
| Jun 30, 2022 | -46.93% |
| Mar 31, 2022 | -40.73% |
| Dec 31, 2021 | -33.28% |
| Sep 30, 2021 | -31.91% |
| Jun 30, 2021 | -30.88% |
| Mar 31, 2021 | -38.19% |
| Dec 31, 2020 | -108.66% |
| Sep 30, 2020 | -288.29% |
| Jun 30, 2020 | -204.34% |
| Mar 31, 2020 | -152.80% |
| Dec 31, 2019 | -120.62% |
| Sep 30, 2019 | -112.91% |
| Jun 30, 2019 | -104.45% |
| Mar 31, 2019 | -78.04% |
| Dec 31, 2018 | -55.77% |
| Sep 30, 2018 | -44.60% |
| Jun 30, 2018 | -36.70% |
| Mar 31, 2018 | -46.19% |